Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
Dmitriy ZamarinOmid HamidAsha Nayak-KapoorSolmaz SahebjamMario SznolAgron CollakuFloyd E FoxMargaret A MarshallDavid S HongPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Mogamulizumab in combination with durvalumab or tremelimumab did not result in potent antitumor efficacy in patients with advanced solid tumors. Tolerability of mogamulizumab 1 mg/kg combined with durvalumab or tremelimumab 10 mg/kg was acceptable.
Keyphrases